ICCM vs NVCR vs ISRG vs MDT vs ABT

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus 2. 7% for IceCure Medical Ltd (ICCM). Abbott Laboratories (ABT) offers the better valuation at 11. 9x trailing P/E (16. 6x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Abbott Laboratories (ABT) is the cheapest at 11.

9x versus Intuitive Surgical, Inc. at 53. 2x. On forward P/E, Medtronic plc is actually cheaper at 14. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Abbott Laboratories wins at 0. 55x versus Medtronic plc's 37. 84x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +51. 2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ISRG returned +493. 3% versus ICCM's -52. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

19β versus NovoCure Limited's 2. 24β — meaning NVCR is approximately 1059% more volatile than ABT relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus 2. 7% for IceCure Medical Ltd (ICCM). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to 20. 0% for IceCure Medical Ltd. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus -445. 6% for IceCure Medical Ltd — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -446. 7% for ICCM. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Abbott Laboratories (ABT) is the more undervalued stock at a PEG of 0. 55x versus Medtronic plc's 37. 84x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Medtronic plc (MDT) trades at 14. 8x forward P/E versus 40. 3x for Intuitive Surgical, Inc. — 25. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 86. 2% to $33. 50.

In this comparison, MDT (3.

4% yield), ABT (2. 4% yield) pay a dividend. ICCM, NVCR, ISRG do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

19), 2. 4% yield, +174. 9% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +174. 9%, NVCR: +51. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ICCM is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; MDT is a mid-cap income-oriented stock; ABT is a mid-cap deep-value stock. MDT, ABT pay a dividend while ICCM, NVCR, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.